These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12700181)

  • 21. Diurnal excretion of urinary cortisol, cortisone, and cortisol metabolites in chronic fatigue syndrome.
    Jerjes WK; Peters TJ; Taylor NF; Wood PJ; Wessely S; Cleare AJ
    J Psychosom Res; 2006 Feb; 60(2):145-53. PubMed ID: 16439267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome.
    Dinan TG; Majeed T; Lavelle E; Scott LV; Berti C; Behan P
    Psychoneuroendocrinology; 1997 May; 22(4):261-7. PubMed ID: 9226729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary cortisol and cortisol metabolite excretion in chronic fatigue syndrome.
    Jerjes WK; Taylor NF; Peters TJ; Wessely S; Cleare AJ
    Psychosom Med; 2006; 68(4):578-82. PubMed ID: 16868267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood trauma and risk for chronic fatigue syndrome: association with neuroendocrine dysfunction.
    Heim C; Nater UM; Maloney E; Boneva R; Jones JF; Reeves WC
    Arch Gen Psychiatry; 2009 Jan; 66(1):72-80. PubMed ID: 19124690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The HPA axis in the pathogenesis of chronic fatigue syndrome].
    Ursini F; Succurro E; Grembiale A; Gagliardi DA; Arturi F
    Clin Ter; 2010; 161(5):461-4. PubMed ID: 20949245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
    Cleare AJ; O'Keane V; Miell JP
    Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroaetiology of chronic fatigue syndrome: an overview.
    Sanders P; Korf J
    World J Biol Psychiatry; 2008; 9(3):165-71. PubMed ID: 17853290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test.
    Papadopoulos A; Ebrecht M; Roberts AD; Poon L; Rohleder N; Cleare AJ
    J Affect Disord; 2009 Jan; 112(1-3):289-94. PubMed ID: 18573538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model-based therapeutic correction of hypothalamic-pituitary-adrenal axis dysfunction.
    Ben-Zvi A; Vernon SD; Broderick G
    PLoS Comput Biol; 2009 Jan; 5(1):e1000273. PubMed ID: 19165314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats.
    Surapaneni DK; Adapa SR; Preeti K; Teja GR; Veeraragavan M; Krishnamurthy S
    J Ethnopharmacol; 2012 Aug; 143(1):91-9. PubMed ID: 22771318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome.
    Scott LV; Burnett F; Medbak S; Dinan TG
    Psychol Med; 1998 Mar; 28(2):285-93. PubMed ID: 9572086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome.
    Neeck G; Crofford LJ
    Rheum Dis Clin North Am; 2000 Nov; 26(4):989-1002. PubMed ID: 11084955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic Fatigue Syndrome and DNA Hypomethylation of the Glucocorticoid Receptor Gene Promoter 1F Region: Associations With HPA Axis Hypofunction and Childhood Trauma.
    Vangeel E; Van Den Eede F; Hompes T; Izzi B; Del Favero J; Moorkens G; Lambrechts D; Freson K; Claes S
    Psychosom Med; 2015 Oct; 77(8):853-62. PubMed ID: 26230484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The neuroendocrinology of chronic fatigue syndrome: focus on the hypothalamic-pituitary-adrenal axis.
    Scott LV; Dinan TG
    Funct Neurol; 1999; 14(1):3-11. PubMed ID: 10321324
    [No Abstract]   [Full Text] [Related]  

  • 35. [Activity of hypotnalamic-pituitary-adrenal axis by induction of experimental chronic fatigue syndrom].
    Fomicheva EE; Filatenkova TA; Rybakina EG
    Ross Fiziol Zh Im I M Sechenova; 2009 Jan; 95(1):11-8. PubMed ID: 19323439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small adrenal glands in chronic fatigue syndrome: a preliminary computer tomography study.
    Scott LV; Teh J; Reznek R; Martin A; Sohaib A; Dinan TG
    Psychoneuroendocrinology; 1999 Oct; 24(7):759-68. PubMed ID: 10451910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis.
    Dekkers JC; Geenen R; Godaert GL; Glaudemans KA; Lafeber FP; van Doornen LJ; Bijlsma JW
    J Rheumatol; 2001 Jul; 28(7):1496-504. PubMed ID: 11469453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome.
    Crofford LJ; Young EA; Engleberg NC; Korszun A; Brucksch CB; McClure LA; Brown MB; Demitrack MA
    Brain Behav Immun; 2004 Jul; 18(4):314-25. PubMed ID: 15157948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does hypothalamic-pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect a 'crash' in the stress system?
    Van Houdenhove B; Van Den Eede F; Luyten P
    Med Hypotheses; 2009 Jun; 72(6):701-5. PubMed ID: 19237251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals.
    Glass JM; Lyden AK; Petzke F; Stein P; Whalen G; Ambrose K; Chrousos G; Clauw DJ
    J Psychosom Res; 2004 Oct; 57(4):391-8. PubMed ID: 15518675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.